Kadmon — Technical Presentation (November 2019)
16 slides from Kadmon's technical presentation, Nov 13, 2019
Slide 1: KD025-213: Pivotal Trial of KD025 in cGVHD Interim Analysis Topline Results
g Kadmon KD025-213: Pivotal Trial of KDO25 in c@VHD Interim Analysis Topline Results November 11, 2019
Slide 2: Forward-Looking Statement
Forward-Looking Statement This presentation contains “forward-looking” statements that are based on the beliefs and assumptions of, and on information currently available to, management of Kadmon Holdings, Inc. (the “Company’). All statements other than statements of historical fact contained in thi
Slide 3: CEO Opening Remarks
CEO Opening Remarks Harlan W. Waksal, M.D., President and CEO
Slide 4: Interim Analysis Outcomes
KD025-213: Interim Analysis Outcomes e KDO025 met the primary endpoint at the interim analysis of the pivotal trial in C6VHD (KD025-213) e KD025 achieved statistically significant and clinically meaningful Overall Response Rates (ORRs): — 64% ORR with KD025 200 mg QD (95% Cl: 51%, 75%) — 67% ORR wit
Slide 5: KD025-208: Updated Results
KD025-208: Updated Results Phase 2 Clinical Trial of KD025 in c6VHD Sanjay Aggarwal, M.D., SVP, Clinical Development
Slide 6: KD025-208: Phase 2a Study of KD025 for Patients with cGVHD
KD025-208: Phase 2a Study of KD025 for Patients with c@VHD jated September 2016; Conducted at 7 + Adults who have had allogeneic hematopoietic cell transplantation (HCT) with steroid-dependent or steroid-refractory cGVHD + Have persistent active cGVHD after at least 2 months of steroid therapy + Rec
Slide 7: KD025-208: Updated Data With Additional Months of Follow-up
KD025-208: Updated Data With Additional 6 Months of Follow-up Data as of 8-Mar-2019 25-208 ORR Clinically Meaningful and Durable Responses e ORRs of ~65% across all 3 cohorts 200 mg QD/200 mg BID| 400 mg QD — Responses observed in all organ systems, including in organs with fibrotic disease — Median
Slide 8: Interim Analysis Results
KD025-213: Interim Analysis Results Pivotal Clinical Trial of KD025 in c6VHD
Slide 9: Ongoing Pivotal Trial of KD025 in cGVHD
KD025-213: Ongoing Pivotal Trial of KD025 in cGVHD KD025-213 (ROCKstar): A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy Primary Endpoint: + ORR, per 2014 NIH criteria KD025 200
Slide 10: Fully Enrolled in Less Than Months
KD025-213: Fully Enrolled in Less Than 10 Months 40 e Conducted at 32 U.S. sites e First Patient In: Oct 2018 e Last Patient In: Aug 2019 100 e Final mITT/ safety: n=132 — 66 patients per arm 120 80 60 Number of Patients 40 20 Ne NO > nw» » A Ne Ae AD ga gga pk gat go WT 99 a” od ail? gee
Slide 11: Real-World Patient Population
KD025-213: Real-World Patient Population Demographics and Baseline Characteristics Median age [years (range)] 53 (21-77) 57 (21-77) Male (%) 64 50 Median prior lines of therapy 3 4 Median time from cGVHD diagnosis to enrollment (months) 25 30 24 Organs Involved [n (%)] 34 (52%) 35 (53%) Median predn
Slide 12: Statistical Analysis Plan
KD025-213: Statistical Analysis Plan Primary Endpoint: ORR Statistical significance is achieved if the lower bound of the 95% Cl of ORR exceeds 30% SS Interim Analysis 2 months after completion Reported November 2019 of enrollment (Oct 2019) Primary Analysis 6 months after completion Planned Q1 2020
Slide 13: KD025-213 Met Primary Endpoint at Interim Analysis
KD025-213 Met Primary Endpoint at Interim Analysis ORR Results Have Exceeded Threshold For Success e KD025 achieved clinically and statistically 90% significant ORRs in both arms 64% 67% e KD025 has been well tolerated (J : 2 (95% Cl: 51%, 75%)! (95% Cl: 54%, 78%) — AEs have been consistent with tho
Slide 14: Closing Remarks
Closing Remarks Harlan W. Waksal, M.D., President and CEO
Slide 15: KD025 in cGVHD: Path Forward
KDO025 in cGVHD: Path Forward e KD025 met the primary endpoint at interim analysis of pivotal trial in c6VHD (KD025-213) — 64% ORR with KD025 200 mg QD (95% Cl: 51%, 75%) — 67% ORR with KD025 200 mg BID (95% Cl: 54%, 78%) e FDA granted Breakthrough Therapy Designation to KD025 in cGVHD after at leas
Slide 16: Q&A
Q&A
Kadmon Holdings — Technical Presentation (November 2019) on 6ix